Cargando…
History of autoimmune conditions and lymphoma prognosis
Autoimmune conditions are strong risk factors for developing lymphoma, but their role in lymphoma prognosis is less clear. In a prospective cohort study, we evaluated self-reported history of eight autoimmune conditions with outcomes in 736 diffuse large B-cell, 703 follicular, 302 marginal zone (MZ...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070501/ https://www.ncbi.nlm.nih.gov/pubmed/30069001 http://dx.doi.org/10.1038/s41408-018-0105-4 |
_version_ | 1783343677143252992 |
---|---|
author | Kleinstern, Geffen Maurer, Matthew J. Liebow, Mark Habermann, Thomas M. Koff, Jean L. Allmer, Cristine Witzig, Thomas E. Nowakowski, Grzegorz S. Micallef, Ivana N. Johnston, Patrick B. Inwards, David J. Thompson, Carrie A. Feldman, Andrew L. Link, Brian K. Flowers, Christopher Slager, Susan L. Cerhan, James R. |
author_facet | Kleinstern, Geffen Maurer, Matthew J. Liebow, Mark Habermann, Thomas M. Koff, Jean L. Allmer, Cristine Witzig, Thomas E. Nowakowski, Grzegorz S. Micallef, Ivana N. Johnston, Patrick B. Inwards, David J. Thompson, Carrie A. Feldman, Andrew L. Link, Brian K. Flowers, Christopher Slager, Susan L. Cerhan, James R. |
author_sort | Kleinstern, Geffen |
collection | PubMed |
description | Autoimmune conditions are strong risk factors for developing lymphoma, but their role in lymphoma prognosis is less clear. In a prospective cohort study, we evaluated self-reported history of eight autoimmune conditions with outcomes in 736 diffuse large B-cell, 703 follicular, 302 marginal zone (MZL), 193 mantle cell (MCL), 297 Hodgkin lymphoma (HL), and 186 T-cell lymphomas. We calculated event-free survival (EFS) and overall survival (OS), and estimated hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for sex, prognostic score, and treatment. History of any of the eight autoimmune conditions ranged from 7.4% in HL to 18.2% in MZL, and was not associated with EFS or OS for any lymphoma subtype. However, there was a positive association of autoimmune conditions primarily mediated by B-cell responses with inferior EFS in MCL (HR = 2.23, CI: 1.15–4.34) and HL (HR = 2.63, CI: 1.04–6.63), which was largely driven by rheumatoid arthritis. Autoimmune conditions primarily mediated by T-cell responses were not found to be associated with EFS or OS in any lymphoma subtype, although there were few events for this exposure. Our results indicate that distinguishing autoimmune conditions primarily mediated by B-cell/T-cell responses may yield insight regarding the impact of this comorbid disease, affecting ~10% of lymphoma patients, on survival. |
format | Online Article Text |
id | pubmed-6070501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60705012018-08-02 History of autoimmune conditions and lymphoma prognosis Kleinstern, Geffen Maurer, Matthew J. Liebow, Mark Habermann, Thomas M. Koff, Jean L. Allmer, Cristine Witzig, Thomas E. Nowakowski, Grzegorz S. Micallef, Ivana N. Johnston, Patrick B. Inwards, David J. Thompson, Carrie A. Feldman, Andrew L. Link, Brian K. Flowers, Christopher Slager, Susan L. Cerhan, James R. Blood Cancer J Article Autoimmune conditions are strong risk factors for developing lymphoma, but their role in lymphoma prognosis is less clear. In a prospective cohort study, we evaluated self-reported history of eight autoimmune conditions with outcomes in 736 diffuse large B-cell, 703 follicular, 302 marginal zone (MZL), 193 mantle cell (MCL), 297 Hodgkin lymphoma (HL), and 186 T-cell lymphomas. We calculated event-free survival (EFS) and overall survival (OS), and estimated hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for sex, prognostic score, and treatment. History of any of the eight autoimmune conditions ranged from 7.4% in HL to 18.2% in MZL, and was not associated with EFS or OS for any lymphoma subtype. However, there was a positive association of autoimmune conditions primarily mediated by B-cell responses with inferior EFS in MCL (HR = 2.23, CI: 1.15–4.34) and HL (HR = 2.63, CI: 1.04–6.63), which was largely driven by rheumatoid arthritis. Autoimmune conditions primarily mediated by T-cell responses were not found to be associated with EFS or OS in any lymphoma subtype, although there were few events for this exposure. Our results indicate that distinguishing autoimmune conditions primarily mediated by B-cell/T-cell responses may yield insight regarding the impact of this comorbid disease, affecting ~10% of lymphoma patients, on survival. Nature Publishing Group UK 2018-08-01 /pmc/articles/PMC6070501/ /pubmed/30069001 http://dx.doi.org/10.1038/s41408-018-0105-4 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Kleinstern, Geffen Maurer, Matthew J. Liebow, Mark Habermann, Thomas M. Koff, Jean L. Allmer, Cristine Witzig, Thomas E. Nowakowski, Grzegorz S. Micallef, Ivana N. Johnston, Patrick B. Inwards, David J. Thompson, Carrie A. Feldman, Andrew L. Link, Brian K. Flowers, Christopher Slager, Susan L. Cerhan, James R. History of autoimmune conditions and lymphoma prognosis |
title | History of autoimmune conditions and lymphoma prognosis |
title_full | History of autoimmune conditions and lymphoma prognosis |
title_fullStr | History of autoimmune conditions and lymphoma prognosis |
title_full_unstemmed | History of autoimmune conditions and lymphoma prognosis |
title_short | History of autoimmune conditions and lymphoma prognosis |
title_sort | history of autoimmune conditions and lymphoma prognosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070501/ https://www.ncbi.nlm.nih.gov/pubmed/30069001 http://dx.doi.org/10.1038/s41408-018-0105-4 |
work_keys_str_mv | AT kleinsterngeffen historyofautoimmuneconditionsandlymphomaprognosis AT maurermatthewj historyofautoimmuneconditionsandlymphomaprognosis AT liebowmark historyofautoimmuneconditionsandlymphomaprognosis AT habermannthomasm historyofautoimmuneconditionsandlymphomaprognosis AT koffjeanl historyofautoimmuneconditionsandlymphomaprognosis AT allmercristine historyofautoimmuneconditionsandlymphomaprognosis AT witzigthomase historyofautoimmuneconditionsandlymphomaprognosis AT nowakowskigrzegorzs historyofautoimmuneconditionsandlymphomaprognosis AT micallefivanan historyofautoimmuneconditionsandlymphomaprognosis AT johnstonpatrickb historyofautoimmuneconditionsandlymphomaprognosis AT inwardsdavidj historyofautoimmuneconditionsandlymphomaprognosis AT thompsoncarriea historyofautoimmuneconditionsandlymphomaprognosis AT feldmanandrewl historyofautoimmuneconditionsandlymphomaprognosis AT linkbriank historyofautoimmuneconditionsandlymphomaprognosis AT flowerschristopher historyofautoimmuneconditionsandlymphomaprognosis AT slagersusanl historyofautoimmuneconditionsandlymphomaprognosis AT cerhanjamesr historyofautoimmuneconditionsandlymphomaprognosis |